GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » PE Ratio (TTM)

RayzeBio (RayzeBio) PE Ratio (TTM) : At Loss (As of Jun. 09, 2024)


View and export this data going back to 2023. Start your Free Trial

What is RayzeBio PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-06-09), RayzeBio's share price is $62.49. RayzeBio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.63. Therefore, RayzeBio's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for RayzeBio's PE Ratio (TTM) or its related term are showing as below:

RYZB' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



RYZB's PE Ratio (TTM) is not ranked
in the Biotechnology industry.
Industry Median: 26.27 vs RYZB: At Loss

RayzeBio's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-1.26. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.63.

As of today (2024-06-09), RayzeBio's share price is $62.49. RayzeBio's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.63. Therefore, RayzeBio's PE Ratio without NRI for today is At Loss.

RayzeBio's EPS without NRI for the three months ended in Sep. 2023 was $-1.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.63.

RayzeBio's EPS (Basic) for the three months ended in Sep. 2023 was $-1.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.63.


RayzeBio PE Ratio (TTM) Historical Data

The historical data trend for RayzeBio's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio PE Ratio (TTM) Chart

RayzeBio Annual Data
Trend Dec20 Dec21 Dec22
PE Ratio (TTM)
N/A N/A N/A

RayzeBio Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23
PE Ratio (TTM) Get a 7-Day Free Trial N/A N/A N/A N/A At Loss

Competitive Comparison of RayzeBio's PE Ratio (TTM)

For the Biotechnology subindustry, RayzeBio's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RayzeBio's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where RayzeBio's PE Ratio (TTM) falls into.



RayzeBio PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

RayzeBio's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=62.49/-1.625
=At Loss

RayzeBio's Share Price of today is $62.49.
RayzeBio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.63.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


RayzeBio  (NAS:RYZB) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


RayzeBio PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of RayzeBio's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


RayzeBio (RayzeBio) Business Description

Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121
RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.
Executives
Hauwermeiren Timothy Van director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi director SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p. 10 percent owner 280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song director, officer: President and Chief Executive C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran officer: Chief Medical Officer 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p. 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129